The company serves as a model for businesses that aim to support veterans, achieving a 240+% increase in veteran hires since 2020 and expanding initiatives to extend assistance in 2023 and beyond...

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in...

BTX-9341 demonstrated potent degradation of CDK4/6 and tumor growth regression in resistant cells in preclinical breast cancer models, along with robust blood brain barrier penetration SOS1...

Vorasidenib data from the INDIGO Phase 3 trial adds to the body of evidence on the impact of targeting the IDH mutation in cancer with the first major advancement in low-grade glioma in 23 years...

- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023...